Related Experiment Videos
Hürthle cell carcinoma: a 60-year experience
Alexander Stojadinovic1, Axel Hoos, Ronald A Ghossein
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Annals of Surgical Oncology
|March 13, 2002
Summary
Hürthle cell cancer (HCC) prognosis is predicted by invasion extent, size, extrathyroidal extension, and metastasis. Recurrence indicates poor outcome, suggesting adjuvant therapy for high-risk patients.
Area of Science:
- Endocrinology
- Oncology
- Surgical Pathology
Background:
- Hürthle cell cancer (HCC) is a rare thyroid malignancy.
- Understanding its clinical behavior and prognostic factors is crucial for patient management.
Purpose of the Study:
- To define the clinical behavior of Hürthle cell cancer.
- To identify prognostic indicators for outcome in HCC patients.
Main Methods:
- Retrospective analysis of 56 confirmed HCC cases treated between 1940 and 2000.
- Kaplan-Meier method and log-rank test used for relapse-free survival (RFS) and disease-specific survival (DSS) analysis.
Main Results:
- Extent of thyroid resection did not predict outcome.
- Degree of invasion, tumor size >4 cm, extrathyroidal extension, and initial metastases were significant adverse predictors of RFS and DSS.
- Eight-year RFS was 100% for low-risk and 24% for high-risk groups; 8-year DSS was 100% and 58%, respectively.
Conclusions:
- Widely invasive HCC is aggressive, associated with high recurrence and mortality risk.
- Prognosis is reliably predicted by invasion degree, tumor size, extrathyroidal extension, and initial metastasis.
- Recurrence signifies a poor outcome; adjuvant therapy should be considered for high-risk patients.